Self Study Module 3: Measurable/Minimal Residual Disease (MRD) in AML Clinical Practice

Launch Date:
January 28, 2022

Primary Audience:

This educational activity is directed toward care providers of patients with AML, including physicians, NPs, PAs and nurses.

This module will discuss measurable/minimal residual disease in AML clinical practice.

Farhad Ravandi-Kashani, MD

Department of Leukemia, Division of Cancer Medicine
MD Anderson Cancer Center
Houston, TX

Dr. Farhad Ravandi is Janiece and Stephen A. Lasher Professor of Medicine and Chief of Section of Developmental Therapeutics in the Department of Leukemia at the University of Texas – M. D. Anderson Cancer Center. He graduated from the University of London, England and undertook residency and fellowship training at the Baylor College of Medicine and The University of Texas M.D. Anderson Cancer Center. During this time he specialized in the management of hematological malignancies and stem cell transplantation. He then joined the University of Illinois at Chicago as the director of leukemia program and the interim director of stem cell transplant program for three years until he joined the Leukemia department of M. D. Anderson in 2003. Dr. Ravandi is board certified in Internal Medicine, Hematology and Medical Oncology. His main areas of interests are therapy of acute myeloid leukemia, as well as rare leukemias including Philadelphia positive acute lymphoblastic leukemia, hairy cell leukemia and T-cell leukemias. He has authored several book chapters and many articles in peer-reviewed journals. He is a member of several professional societies including the American Society of Hematology, American Society of Clinical Oncology, and Society of Hematological Oncology and is a member of editorial board of several journals.

Nicole Chambers, FNP-BC

Nurse Practitioner
Hematology Oncology Department
Montefiore Medical Center
New York, NY

Nicole Chambers, NP is a Family Medicine Nurse Practitioner in the Bronx, NY. Having more than 4 years of diverse experiences she practices in the Hematology Oncology Department at Montefiore Medical Center. 

1.
Incorporate knowledge of currently available MRD testing methods to best assess residual disease in patients with AML.